Monday, August 24, 2026
22.7 C
Bengaluru

Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025

1. Market Overview The oncology sector remains the most dominant area in healthcare, with over 50% of ongoing clinical trials focused on cancer treatment. In 2023, the global oncology market was valued at $222.36 billion and is projected to reach $521.6 billion by 2033, growing at a CAGR of 8.9% from 2024 onward. With personalized…

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

How To Power The India Biopharma Regulatory Revolution Now

Beyond the Pharmacy of the World: Why India's Biopharma...

Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?

Something remarkable has happened in the Indian pharmaceutical market....

Can India Pivot From Low-Cost Medical Tourism to Trusted Medical Value Travel?

C-Suite Executive Summary India stands at a pivotal juncture in...

Rajesh Bhogavalli has been appointed as Chief Commercial Officer of ACG Group.

With over 25 years of leadership experience across commercial...

Will President Trump’s Diktat Improve Drug Quality For Indian Patients?

Executive Summary The geopolitical landscape of pharmaceutical manufacturing is shifting...

Topics

How To Power The India Biopharma Regulatory Revolution Now

Beyond the Pharmacy of the World: Why India's Biopharma...

Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?

Something remarkable has happened in the Indian pharmaceutical market....

Can India Pivot From Low-Cost Medical Tourism to Trusted Medical Value Travel?

C-Suite Executive Summary India stands at a pivotal juncture in...

Will President Trump’s Diktat Improve Drug Quality For Indian Patients?

Executive Summary The geopolitical landscape of pharmaceutical manufacturing is shifting...

Mounjaro is the Exceptional Growth Story: Ranks #1

The July Brand Monitor by Pharmarack shows a healthy...

Sun Pharma: In the Eye of the Storm of Ophthalmologists

The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance,...

Does India Need to Reinvent the Wheel on Junk Foods?

In a written reply in the Lok Sabha in...
spot_img

Related Articles

spot_imgspot_img